Monday, June 15, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 955 of 1,261

  1. US 7998490

    Genes of an otitis media isolate of nontypeable Haemophilus influenzae

    The Board of Regents of the University of Oklahoma · Granted Aug 16, 2011 · Expires Aug 11, 2031

    granted

  2. US 7999113

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Aug 16, 2011 · Expires Aug 11, 2031

    granted

  3. US 7993919

    Method of inducing memory B cell development and terminal differentiation

    The United States of America, as represented by the Department of Health and Human Services · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  4. US 7993865

    Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen

    The Regents of the University of California · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  5. US 7993866

    Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

    The Regents of the University of California · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  6. US 7993690

    Carbohydrate and electrolyte replacement composition

    Stokely-Van Camp, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  7. US 7993046

    Flexible light-emitting apparatus

    United Lighting Opto-Electronic Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  8. US 7993857

    Determination of AM-binding proteins and the association of adrenomedullin (AM) therewith

    The United States of America, as represented by the Department of Health and Human Services · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  9. US 7994165

    Aryl aniline derivatives as β2 adrenergic receptor agonists

    Theravance, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  10. US 7994320

    Narcistatin prodrugs

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  11. US 7994332

    Process for producing crystal

    Takeda Pharmaceutical Company Limited · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  12. US 7993867

    Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

    The Regents of the University of California · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  13. US 7994299

    Compositions and methods for increasing bone mineralization

    Darwin Discovery Limited · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  14. US 7994307

    RNAi modulation of the BCR-ABL fusion gene and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  15. US 7994309

    Compositions and methods for inhibiting expression of a mutant gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  16. US 7994306

    Methods of treating cancer using siRNA molecules directed against CD24

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  17. US 7994272

    Maleamic acid polymer derivatives and their bioconjugates

    Nektar Therapeutics · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  18. US 7994217

    Prenatal multivitamin/multimineral supplement

    Xanodyne Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  19. US 7994211

    Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses

    Argenta Discovery Limited · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  20. US 7994226

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  21. US 7994209

    3-phenoxymethylpyrrolidine compounds

    Theravance, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  22. US 7994193

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    ACADIA Pharmaceuticals Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  23. US 7994183

    Solid preparation comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile

    Takeda Pharmaceutical Company Limited · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  24. US 7994191

    Heterocyclic cyclopamine analogs and methods of use thereof

    Infinity Discovery, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.